Table IV.I.

Association between body mass index (BMI) and hormones stratified by menopausal status¹: Means ± SE among a sample of 667 women with breast cancer.²

	BMI < 25	BMI: 25–30	BMI ≥ 30	P for trend
	Mean ± SE (n = 284)	Mean ± SE (n = 216)	Mean ± SE (n = 210)
C-Peptide (ng/mL)
Premenopausal	1.54 ± 0.09	1.92 ± 0.11a	2.69 ± 0.13b c	.0001
Postmenopausal	1.89 ± 0.07	2.45 ± 0.08a	2.95 ± 0.08b c	.0001
Leptin (ng/mL)
Premenopausal	10.8 ± 1.4	18.7 ± 1.7a	36.9 ± 2.0b c	.0001
Postmenopausal	13.4 ± 0.9	24.8 ± 1.0a	43.0 ± 1.1b c	.0001
IGF-1 (ng/mL)
Premenopausal	168.7 ± 6.6	166.0 ± 8.1	149.4 ± 9.7	.11
Postmenopausal	134.9 ± 3.6	128.9 ± 4.0	110.1 ± 4.2b c	.0001
IGFBP-3 (ug/mL)
Premenopausal	4.09 ±0.10	4.10 ± 0.16	4.31 ± 0.15	.24
Postmenopausal	4.10 ±0.07	4.07 ± 0.07	4.00 ± 0.08	.33
IGF-I:IGFBP-3 (ng/mL)
Premenopausal	41.5 ± 1.4	40.3 ± 1.7	35.1 ± 2.0b c	.013
Postmenopausal	32.8 ± 0.7	31.7 ± 0.8	27.7 ± 0.8b c	.0001

¹Sample sizes for premenopausal women: BMI < 25: N = 63, BMI: 25–30: N = 41; BMI ≥30: N = 30; Postmenopausal women: BMI < 25: N = 210, BMI: 25–30: N = 165; BMI ≥30: N = 158.

²Adjusted for study site, age, ethnicity, education, disease stage, adjuvant treatment, tamoxifen use, type 2 diabetes, smoking status, and sports/recreational MET-hr/week

^aBMI 25–29.9 significantly different from BMI < 25, p < .05.

^bBMI ≥30 significantly different from BMI < 25, p < .05.

^cBMI ≥30significantly different from BMI 25.0 – 29.9, p < .05.